The United States Patent and Trademark Office (USPTO) today announced the selection of 19 law schools that will join the USPTO’s Law School Clinic Certification Pilot Program this fall. Indiana University School of Law was one of five law schools selected to join both the Patent and Trademark portions of the Program.
The participating law school clinical programs provide patent and trademark legal services to independent inventors and small businesses on a pro bono basis. Clinic clients can expect to receive searches and opinions, advice from clinic law students regarding their intellectual property (IP) needs under the supervision of a faculty practitioner, drafting and filing of applications, and representation before the USPTO.
The law school clinical programs possess solid Intellectual Property curricula supporting a participating student’s hands-on learning in the Program; a commitment to networking in the community; comprehensive pro bono services; and excellent case management systems. Students in the patent and/or trademark portions of the Program can expect to draft and file applications and respond to Office Actions.
Click here for the full USPTO announcement and a list of all schools selected to participate in the Certification Pilot Program.
I spent this week in Philadelphia, the City of Brotherly Love. It was my first visit and I have to say the place is top-rate. Some of the best museums you can imagine and the C-SPAN junkie in me was absolutely thrilled to walk inside Congress Hall, location of the first U.S. House and Senate from 1790-1800. But just because I’m out sightseeing doesn’t mean the news stops. Here are the top stories I followed this week:
An intriguing story of patent litigation and “patent trolls” featuring a Lafayette law firm, Dowell Baker.
“Dowell Baker, a law firm specializing in patent litigation in Lafayette, Indiana, finds companies to target in a couple different ways. The firm’s client, ArrivalStar, holds 34 U.S. patents, all related to the idea of tracking a vehicle in motion and then alerting people, through some communications device, of when it may arrive or whether it’s running late. As you might imagine, many entities – airlines, school buses, freight-tracking services, package-delivery companies – do something quite similar to this. And Dowell Baker believes they’re all infringing on these patents.”
“As we’ve seen, our constitutional system requires limits on copyright as a way to assure that copyright holders do not too heavily influence the development and distribution of our culture.” -Lawrence Lessig
The Intellectual Property Law and Innovation Symposium at Indiana University School of Law – Indianapolis on Dec. 2 will focus on recent changes to patent law created by the America Invents Act (AIA).
The Center for Intellectual Property Law and Innovation has assembled a distinguished group to analyze the AIA from a variety of perspectives, focusing on the Act’s implications for the life sciences. Speakers include a legendary patent law jurist, patent reform leaders, chief corporate patent counsel, leading practitioners and scholars, as well as the PTO’s Patent Reform Coordinator.
The event carries 4.5 hours of CLE credit, pending approval. Registration is $125, which includes materials, refreshments and lunch. The event runs from noon to 6 p.m. at the law school, 530 W. New York St., Indianapolis. For more information, visit the law school’s website.
For others, this act has been labeled an “innovation killer,” handing over market control to large corporations, driving inventors and potential entrepreneurs back into their labs to toil in secret, and basically halting America’s leadership in research and development.
For Indiana’s life sciences sector, it both raises hopes and creates challenges for continued growth.
For large or small companies, the product development life cycle for a biological therapy comes with a lot of risk. It can take a decade or more and over $1 billion to bring a product to market, and the product can fail at pretty much any point in that process. For the majority of the time in development, a company’s intellectual property is its primary asset.
For larger companies, that risk is spread across multiple products (the company’s pipeline); for smaller companies, everything may depend on the success or failure of a single molecule or protein. Large or small, intellectual property plays a huge role in a life sciences company’s valuation and business strategy.